Bria-IMT Plus Checkpoint Inhibition Maintains Favorable OS in Metastatic Breast Cancer
Bria-IMT (SV-BR-1-GM) combined with retifanlimab-dlwr or pembrolizumab showed improved overall survival (OS) and progression-free survival (PFS) in heavily pretreated metastatic breast cancer patients, with median OS of 15.6 months and PFS of 4.1 months in the 2022 cohort, and 13.4 months OS and 3.9 months PFS since study onset. These results support Bria-IMT's potential as a new standard of care.
Related Clinical Trials
Reference News
Bria-IMT (SV-BR-1-GM) combined with retifanlimab-dlwr or pembrolizumab showed improved overall survival (OS) and progression-free survival (PFS) in heavily pretreated metastatic breast cancer patients, with median OS of 15.6 months and PFS of 4.1 months in the 2022 cohort, and 13.4 months OS and 3.9 months PFS since study onset. These results support Bria-IMT's potential as a new standard of care.